Corrigendum to "ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance" [Blood Cells Mol. Dis. 53, (1-2), (June-August 2014) 47-55], doi:10.1016/j.bcmd.2014.02.008;ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 1-2, 2014, Pages 47-55

  Ferreira, A F ^a   Moura, L G ^a   Tojal, I ^b   Ambrosio L ^a   Pinto Simoes B ^a   Hamerschlak, N ^c   Calin, G A ^d   Ivan, C ^d   Covas, D T ^a,b   Kashima, S ^b   Castro, F A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Centro Regional de Hemoterapia de Ribeirão Preto   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Chronic myeloid leukemia; Imatinib response; MicroRNA

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; MICRORNA; MICRORNA 130A; MICRORNA 130B; MICRORNA 142 3P; MICRORNA 146A; MICRORNA 15A; MICRORNA 16; MICRORNA 21; MICRORNA 26A; MICRORNA 29C; MICRORNA LET 7D; MICRORNA LET 7E; PHOSPHOTYROSINE; RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BCR ABL GENE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; YOUNG ADULT; ADOLESCENT; APOPTOSIS; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900030676     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.08.005     Document Type: Erratum

References (29)

1. Melo J.V., Barnes D.J. Chronic myeloid leukemia as a model of disease evolution in human cancer. Nature 2007, 7:441-450.
2. Deininger M.W., Vieira S., Mendiola R., et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. 2000, 60:2049-2055.
3. Amarante-Mendes G.P., Green D.R. The regulation of apoptotic cell death. Braz. J. Med. Biol. Res. 1999, 32:1053-1061.
4. Gutierrez-Castellanos S., Cruz M., Rabelo L., et al. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur. J. Haematol. 2004, 72:231-238.
5. Aichberger K.J., Mayerhofer M., Krauth M.T., et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105:3303-3311.
6. Perrotti D., Neviani P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin. Cancer Res. 2007, 13:1638-1642.
7. Faderl S., Kantarjian H.M., Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology 1999, 13:169-180.
8. Cheng Y., Ji R., Yue J., et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?. Am. J. Pathol. 2007, 170:1831-1840.
9. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. PNAS 2005, 102:13944-13949.
10. Zanette D.L., Rivadavia F., Molfetta G.A., et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 2007, 40:1435-1440.
11. Seca H., Almeida G.M., Guimarães J.E., Vasconcelos M.H. miR signatures and the role of miRs in acute myeloid leukaemia. Eur. J. Cancer 2010, 46:1520-1527.
12. Careta F.P. Expression of Genes Involved in Cell Proliferation and Apoptosis in Chronic Lymphocytic Leukemia 2007, Master Degree Thesis, Faculty of Medicine of Ribeirão Preto-University of São Paulo, (75 pp.).
13. Bueno-da-Silva A.E., Brumatti G., Russo F.O. Bcr-Abl1-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ. 2003, 10:592-598.
14. Guo W., Liu R., Ono Y., et al. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol. Pharmacol. 2012, 82:938-947.
15. Rokah O.H., Granot G., Ovcharenko A., et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One 2012, 7:35501.
16. Suresh S., McCallum L., Lu W. MicroRNAs 130a/130b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J. Cell Commun. Signal. 2011, 5:183-191.
17. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
18. Nuovo G.J., Garofalo M., Valeri N., et al. Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod. Pathol. 2012, 25:1333-1344.
19. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
20. Xiong Y., Fang J.H., Yun J.P., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
21. Spinello I., Quaranta M.T., Riccioni R., et al. MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer J. 2011, 1(6):e26.
22. Wei W., Huang H., Zhao S., et al. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion. Apoptosis 2013, 18(9):1060-1070.
23. Métais J.Y., Winkler T., Geyer J.T., et al. BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation. PLoS One 2012, 7:48267.
24. Beverly L.J., Varmus H.E. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009, 28:1274-1279.
25. Brieger A., Boehrer S., Schaaf S., et al. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Biochem. Pharmacol. 2004, 68:85-93.
26. Enériz E.S.J., Gómez J.R., Velasco A.J., et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol. Cancer 2009, 8:69.
27. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
28. Flamant S., Ritchie W., Guilhot J., et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 2010, 95:1325-1333.
29. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.